
Day Return
YTD Return
1-Year Return
3-Year Return
5-Year Return
Note: Sector performance is calculated based on the previous closing price of all sector constituents
Industries in This Sector
Select an Industry for a Visual Breakdown
| Industry | Market Weight | YTD Return | |
|---|---|---|---|
| All Industries | 100.00% | 5.27% | |
| Drug Manufacturers - General | 42.30% | 17.88% | |
| Biotechnology | 12.30% | 1.98% | |
| Medical Devices | 11.44% | -0.57% | |
| Diagnostics & Research | 9.56% | -6.93% | |
| Healthcare Plans | 7.56% | -7.52% | |
| Medical Instruments & Supplies | 6.66% | -3.37% | |
| Medical Distribution | 3.27% | 10.24% | |
| Medical Care Facilities | 3.22% | 11.52% | |
| Drug Manufacturers - Specialty & Generic | 2.56% | 1.94% | |
| Health Information Services | 1.13% | -38.59% | |
| Pharmaceutical Retailers | 0.00% | -15.73% | |
Note: Percentage % data on heatmap indicates Day Return
All Industries
--
<= -3
-2
-1
0
1
2
>= 3
Largest Companies in This Sector
View MoreName | Last Price | 1Y Target Est. | Market Weight | Market Cap | Day Change % | YTD Return | Avg. Analyst Rating |
|---|---|---|---|---|---|---|---|
| 1,020.56 | 1,202.37 | 13.19% | 962.753B | -1.50% | -5.04% | Buy | |
| 244.99 | 231.25 | 8.09% | 590.401B | +0.68% | +18.38% | Buy | |
| 228.72 | 246.63 | 5.54% | 404.236B | -1.78% | +0.10% | Buy | |
| 121.66 | 124.89 | 4.16% | 303.88B | +0.07% | +15.58% | Buy | |
| 288.20 | 364.62 | 3.58% | 261.063B | -0.31% | -12.70% | Buy | |
| 379.73 | 350.04 | 2.80% | 204.674B | +1.71% | +16.02% | Buy | |
| 113.29 | 133.39 | 2.70% | 197.177B | +0.92% | -9.58% | Buy | |
| 513.56 | 666.46 | 2.64% | 192.949B | +2.39% | -11.37% | Buy | |
| 152.74 | 155.42 | 2.60% | 189.501B | -1.63% | +24.44% | Buy | |
| 500.76 | 611.82 | 2.44% | 177.835B | +1.50% | -11.58% | Buy |
Investing in the Healthcare Sector
Start Investing in the Healthcare Sector Through These ETFs and Mutual Funds
ETF Opportunities
View MoreName | Last Price | Net Assets | Expense Ratio | YTD Return |
|---|---|---|---|---|
| 157.67 | 40.98B | 0.08% | +1.85% | |
| 291.42 | 19.812B | 0.09% | +1.24% | |
| 174.76 | 8.534B | 0.44% | +3.55% | |
| 125.60 | 8.336B | 0.35% | +3.01% | |
| 100.94 | 4.621B | 0.40% | +3.63% |
Mutual Fund Opportunities
View MoreName | Last Price | Net Assets | Expense Ratio | YTD Return |
|---|---|---|---|---|
| 209.40 | 39.263B | 0.32% | +2.36% | |
| 88.29 | 39.263B | 0.32% | +2.37% | |
| 145.79 | 19.812B | 0.09% | +1.29% | |
| 134.20 | 15.226B | 0.00% | +0.74% | |
| 11.18 | 15.226B | 0.00% | +0.66% |
Healthcare Research
View MoreDiscover the Latest Analyst and Technical Research for This Sector
Analyst Report: Mettler-Toledo International Inc.
Mettler-Toledo supplies weighing and precision instruments to customers in the life sciences (around 55% of sales), industrial (around 40%), and food retail (around 5%) industries. Its products include laboratory and retail scales, pipettes, pH meters, thermal analysis equipment, titrators, metal detectors, and X-ray analyzers. Mettler leads the market for weighing instrumentation and controls more than 50% of the market for lab balances. The business is geographically diversified, with the Americas accounting for about 37% of sales, Europe about 27%, China about 16% and the rest of the world about 20%.
RatingPrice TargetAnalyst Report: Molina Healthcare, Inc.
Molina Healthcare provides medical insurance plans through Medicaid, the individual exchanges, and Medicare. It manages health benefit risks for more than 5 million people, with more than 85% of those members coming through contracts with state governments for their Medicaid programs. Medicaid contracts in four states—California, New York, Texas, and Washington—account for over half of its enrollees.
RatingPrice TargetAnalyst Report: Bausch + Lomb Corporation
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
RatingPrice TargetAnalyst Report: Labcorp Holdings Inc.
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.
RatingPrice Target


















